FFF Enterprises: BioSupply Trends Newsletter
Monday, Mar 20, 2017

Study to Test Gene Therapy in SCID Patients

 

In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
IVIG / SCIG Rates
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly
 

Over the next five years, a new study will test gene therapy in up to 15 children with X-linked severe combined immunodeficiency as an alternative to stem cell transplants using donor cells that can result in serious infection. [ read more ]

Researchers Receive Grant to Study Most Effective Treatment for Kawasaki Disease

Researchers at University of California San Diego School of Medicine, Rady Children’s Hospital-San Diego and Betty Irene Moore School of Nursing at University of California, Davis, have received a $2 million grant from the Patient-Centered Outcomes Research Institute for a three-year study to look at the effectiveness of two treatment options for children with Kawasaki disease who are resistant to initial therapy. [ read more ]

Study Shows Topical Use of Fibrin Sealant Can Reduce Blood Loss and Need for Transfusion in Total Knee and Hip Arthroplasty

Results of a meta-analysis that assessed the safety and effectiveness of topical administration of fibrin sealants on postoperative blood loss and blood requirements in patients undergoing total hip arthroplasty and total knee arthroplasty showed that it can decrease the need for transfusion, decrease total blood loss, decrease blood drainage loss and shorten the length of hospital stay. [ read more ]

Industry News

 
 

From American Autoimmune Related Disease Association

In honor of National Autoimmune Disease Awareness Month in March, the American Autoimmune Related Disease Association has launched the first registry for patients with multiple sclerosis and other autoimmune diseases.
[ read more ]

From Pfizer

Results of a Phase II clinical trial of Pfizer’s preventive vaccine against Clostridium difficile (C. diff) showed the vaccine was safe and stimulated a C. diff-targeted immune response.  [ read more ]

From Sanofi Pasteur and MedImmune

Sanofi Pasteur, Sanofi’s vaccines global business unit, and MedImmune, the global biologics research and development arm of AstraZeneca, have agreed to develop and commercialize a monoclonal antibody, MEDI8897, for the prevention of respiratory syncytial virus-associated illness in newborns and infants. [ read more ]

IVIG & Albumin Supply Index

 
 

What's New at FFF

Bivalirudin (Fresenius Kabi)

Bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients 1) with unstable angina undergoing percutaneous transluminal coronary angioplasty; 2) undergoing percutaneous coronary intervention (PCI) with provisional use of glycoprotein IIb/IIIa inhibitor as in the REPLACE-2 study; and 3) with, or at risk of, heparin-induced thrombocytopenia or heparin-induced thrombocytopenia and thrombosis syndrome, undergoing PCI. It is available for intravenous use, and is supplied in a single-use vial containing 250 mg of Bivalirudin. It is intended for use with aspirin, and has been studied only in patients receiving concomitant aspirin.

For more information about Bivalirudin, login to biosupply.fffenterprises.com
*Call for eligibility through your GPO affiliation.

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective January 1, 2017, through March 31, 2017.

Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
IVIG
Bivigam J1556 $74.29 $73.10
Carimune NF J1566 $64.08 $63.05
Flebogamma J1572 $65.36 $64.31
Gammagard S/D J1566 $64.08 $63.05
Gammaplex J1557 $78.01 $76.76
Octagam J1568 $70.80 $69.66
Privigen J1459 $77.35 $76.11
SCIG
Cuvitru J3490 / J3590 / J7799 ** **
Hizentra J1559 $98.46 $96.88
HyQvia J1575 $129.69 $127.61
IVIG / SCIG
Gammagard Liquid J1569 $80.39 $79.10
Gammaked J1561 $72.88 $71.71
Gamunex-C J1561 $72.88 $71.71

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.
** Cuvitru does not yet have Medicare rates.

 

Resources

FFF customers may order the following complementary resources to help you with your practice:

•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Home | About | Advertise | Subscribe | Contact – ©2017 FFF Enterprises, Inc.
This email was sent by: %%Member_Busname%%, %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
Manage preferences: Privacy Policy, Update Profile, Unsubscribe.